Clinical Trial Update: Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa [Phase 2]

View source ↗

Summary

Phase 2 trial update on a three-drug therapy (diethylcarbamazine, albendazole, and ivermectin) for lymphatic filariasis completion status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphatic Filariasis

Drugs mentioned

• Albendazole (ALBENDAZOLE)
• Diethylcarbamazine (diethylcarbamazine)
• IVERMECTIN (Ivermectin)

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Lymphatic Filariasis | Phase 2 | Status: COMPLETED